ONCOCYTE CORP (OCX) Stock Income Statement
NASDAQ:OCX - Nasdaq - US68235C2061 - Common Stock - Currency: USD
| TTM (2025-3-31) | 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 3.84M | 1.88M | 1.50M | 960.00K | 2.20M | |||
| Cost Of Goods | 1.82M | 1.14M | 1.09M | 980.00K | 780.00K | |||
| Gross Profit | 2.02M | 740.00K | 413.00K | -20.00K | 1.42M | |||
| Operating Expenses | 18.69M | 19.71M | 16.92M | -2.21M | 52.69M | |||
| Research and Development | 9.36M | 8.80M | 7.88M | 6.97M | 4.81M | |||
| Selling, General, and Administrative Expenses | 14.77M | 13.79M | 13.54M | 21.53M | 20.39M | |||
| Operating Income | -16.67M | -18.97M | -16.51M | 2.19M | -51.27M | |||
| Interest Income/Expense | -98.00K | -84.00K | -113.00K | -550.00K | -250.00K | |||
| Other Income/Expense | 466.00K | 462.00K | 394.00K | -70.00K | -40.00K | |||
| Non Recurring Items | N/A | -42.07M | -8.63M | -20.19M | -1.31M | |||
| Income Before Taxes | -58.20M | -60.66M | -24.86M | -18.61M | -52.87M | |||
| Income Tax | N/A | 0.00 | N/A | 0.00 | -9.26M | |||
| Net Income | -58.26M | -60.93M | -28.72M | -73.42M | -64.10M | |||
| EBITDA | -14.95M | -17.41M | -14.83M | 7.41M | -47.07M | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | -3.52 | -4.66 | -3.75 | -13.25 | -14.40 | |||
| Non GAAP EPS | -3.53 | -4.40 | -3.60 | -13.20 | -0.44 | |||
| Statistics | ||||||||
| Gross Profit Margin | 52.56% | 39.34% | 27.48% | -2.08% | 64.55% | |||
| Profit Margin | -1516.06% | -3239.02% | -1911.04% | -7647.92% | -2913.64% | |||
| Operating Profit Margin | -433.85% | -1008.61% | -1098.20% | 228.13% | -2330.45% | |||
All data in USD